You are here: Home / News / TRADE / Antigen rapid test: this cheap drug used by Trump may treat the COVID-19

Antigen rapid test: this cheap drug used by Trump may treat the COVID-19

Views: 0     Author: Site Editor     Publish Time: 2022-03-03      Origin: Site

The new coronavirus has ravaged the world for 2 years, this cheap drug used by Trump may treat the COVID-19. We also can provide you with related testing products.

Recently, studies have found that famotidine can regulate immunity, completely eliminate histamine receptor-mediated cytokine production, and also has a broad-spectrum antiviral effect.

In the early days of the Covid-19 pandemic, computer-based drug screening experiments suggested that famotidine could play a role in fighting Covid-19. Subsequently, a retrospective analysis of 6,212 Covid-19 patients found that the fatality rate of Covid-19 hospitalized patients who used famotidine was about 14%, while the fatality rate of patients who did not use famotidine was as high as 27%. In 2020, after former US President Trump was infected with the Covid-19, he was treated with a regimen including famotidine and cured three days later.

In vitro experiments showed that famotidine treatment of 2019-nCoV infected cells can inhibit the expression of TLR3 induced by histamine, reduce the transduction of TLR3-dependent inflammatory signals, and control the level of influenza nasal swab - UDXBIO

The good performance of famotidine in the treatment of Covid-19 pneumonia has attracted the attention of Professor Janowitz of the Cold Spring Harbor Laboratory in New York. Prof. Janowitz conducted a small case study[8], including 10 patients with Covid-19, treated with high-dose oral famotidine. All patients reported significant improvement in disease-related symptoms within 48 hours of starting famotidine.

In this randomized, double-blind, placebo-controlled clinical trial, Professor Janowitz recruited 55 mild to moderate COVID-19 outpatients as subjects and divided them into a famotidine group and a placebo group. All subjects received 80 mg of famotidine or placebo three times a day for 14 consecutive days, followed by 14 additional days of monitoring, with final follow-up and symptom assessment on day 60; Measure the new crown symptoms such as fatigue, shortness of breath, cough, headache and loss of smell and taste, and continuously monitor until the symptoms are relieved or for 28 days; Swabs and venous blood were used to detect the new coronavirus, biochemical indicators, famotidine blood concentration and interferon α level.

The baseline characteristics of the two groups of subjects were well matched. The famotidine group and the placebo group had the same average total symptom score and average symptom duration of the new crown, and similar indicators such as age, gender and ethnic composition ratio, body weight index, blood oxygen, temperature and heart rate. The subjects were highly diverse, with almost twice as many female patients as males, and were racially diverse.

The trial found the most common symptoms of COVID-19 outpatients were fatigue, muscle pain, cough, runny nose and shortness of breath. By day 14 of treatment, the proportion of symptomatic subjects in the famotidine group dropped to half of that in the placebo group, and by day 28, symptom remission rates were same in both groups.

In terms of the various symptoms of the new crown, in the 16 related symptoms, 14 of the famotidine group appeared early remission (87.5%), while only 2 (12.5%) in the placebo group. Among them, famotidine can provide early relief of energy deficit, loss of smell or taste, dyspnea, chest tightness and muscle pain.

By analyzing the blood biochemical indicators of the subjects, the researchers found that compared with the placebo group, the patients in the famotidine group had significantly lower plasma interferon alpha levels on the 7th day of the trial (p=0.039). RNA sequencing confirmed that the type I interferon gene score of the patients in the famotidine group was significantly decreased (p=0.032). Among them, the genes OAS1–3 are antiviral proteins induced by type I interferon, which have antiviral activity and have antiviral activity in cells. It plays a key role in the innate immune response, and its expression was also significantly down-regulated in the famotidine group. In addition, the researchers also found that the type I interferon score was correlated with the total symptom score of the new crown, indicating that the severity of the new crown symptoms was related to the degree of interferon-mediated inflammation. Famotidine can reduce the level of type I interferon in patients with new crowns, thereby relieving symptoms of new crowns.

After taking the famotidine group for 7 days, the plasma interferon alpha level (Panel B) was significantly decreased, the type I interferon gene score decreased (Panel C), and the type I interferon gene score was significantly correlated with the symptom score (Panel D), the expression of type I interferon-related gene OSA1-3 (Figure E-G) was down-regulated

In summary, through a small-scale prospective clinical trial, Prof. Janowitz's team observed the efficacy of oral famotidine on mild to moderate non-hospitalized patients with COVID-19, and found that famotidine can reduce type I interferon in patients with COVID-19 level, improve most mild to moderate clinical symptoms of the new crown, and promote the remission of the new crown.